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Abstract
The use of D2/D3 dopaminergic agonists in Parkinson’s disease (PD) may lead to pathological gambling. In a placebo-
controlled double-blind study in healthy volunteers, we observed riskier choices in a lottery task after administration of the
D3 receptor-preferring agonist pramipexole thus mimicking risk-taking behavior in PD. Moreover, we demonstrate
decreased activation in the rostral basal ganglia and midbrain, key structures of the reward system, following unexpected
high gains and therefore propose that pathological gambling in PD results from the need to seek higher rewards to
overcome the blunted response in this system.
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Introduction
The administration of dopaminergic drugs with D2/D3 agonist
activity to Parkinson’s patients, targeting the dopaminergic deficit in
the nigrostriatal pathway in this condition, has recently been
reported to lead to impulse control disorders, in particular
pathological gambling, suggesting a breakdown of reward-hierar-
chies in such patients [1–3]. In the survey conducted by Weintraub
and colleagues [3], about 7 percent of Parkinson’s patients treated
with the popular D2/D3 receptor-preferring agonist pramipexole
developed pathological gambling, while none of the patients
receiving standard treatment with dopamine precursor L-Dopa
showedthiscondition.Thissuggeststhattheprocessingofrewarding
stimuli might be altered under the influence of D2/D3 agonists.
The underlying neural mechanism by which these dopaminer-
gic agents modify the processing of rewarding stimuli and lead to
compulsive gambling remains poorly understood. A recent fMRI
study employing a gambling task found a decreased sensitivity of
the reward system in pathological gamblers [4]. Activation of the
ventral striatum following wins was found to be decreased
compared to healthy control subjects and correlated negatively
with gambling severity [4]. The intensity of the fMRI BOLD
signal in the nucleus accumbens (NAcc) of the ventral striatum has
been found to be directly related with dopamine release in this
structure [5]. In the light of these findings we hypothesized that
dopaminergic D2/D3 agonists may impair the responsiveness of
brain reward systems. Consequently, we expected that neural
activation associated with monetary reward in a gambling task
should be reduced under treatment with pramipexole.
In order to test this hypothesis, we performed a slow event-
related fMRI study in a group of 15 healthy young male volunteers
using a 3 Tesla scanner. A double-blind, placebo-controlled cross-
over design was used with placebo given in one session and 0.5 mg
of pramipexole given 2 hours prior to the scan in the other. A
lottery task was used in which participants could either win or lose
25 or 5 Euro cents in each trial (see Fig. 1). In addition, in a small
proportion of the trials, wins were doubled. The rationale for the
inclusion of such ‘‘boost’’ trials was the finding in animal research
that unexpected wins lead to an increase in phasic activity of
midbrain dopaminergic neurons projecting (among other struc-
tures) to the NAcc [6]. We thus predicted that reward-related
activation of the striatum would be maximal in the boost trials.
Results
The behavioral data (Fig. 2) showed a characteristic relation-
ship between previous outcomes and current choices. The analysis of
the standard outcomes by means of a three-way ANOVA with
treatment (placebo vs. pramipexole), type of previous outcome
(gain vs. loss) and magnitude of outcome (25 or 5) showed a
significant effect of type of previous outcome [F(1,12)=12.4;
p,0.01], with losses in the previous trial leading to riskier choices
(i.e., higher probability of selecting 25) than gains. Although, the
overall number of times that subjects made a risky choice (25 cents)
did not differ between treatments: 47% after placebo and 49%
after pramipexole (t(12)=21.0, p=0.33); the analysis of the
infrequent boost trials by means of a two-way ANOVA with
treatment and type of boost trial (‘‘+50’’ vs. ‘‘+10’’) as factors
showed a main effect of treatment [F(1,12)=5.0, p,0.05].
Pairwise comparisons by means of t-tests showed a significant
effect for the ‘‘+50’’ trials only; t(12)=22.28, p,0.05. Thus,
pramipexole abolished the tendency to be conservative after a
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pattern is consistent with clinical observations of an increase of risk
behavior in Parkinson’s patients treated with dopaminergic
agonists.
Functional MRI results showed that monetary gains (standard
gain plus boost trials vs. losses) in the placebo condition robustly
increased activity in the rostral basal ganglia, in an area
encompasing the globus pallidus and parts of the ventral striatum
(Fig. 3a). At the same threshold, this activation was greatly
diminished under pramipexole. To assess the response pattern in
more detail, the time-course of the blood oxygen level dependent
(BOLD) response in rostral basal ganglia was examined by
defining a region of interest (ROI) around the peak of activation
(x,y,z: 215,23,23) in the globus pallidus. In the placebo
condition, win trials (green; solid: 25 cent wins, dotted: 5 cent
wins) showed an increase in BOLD relative to loss trials (red). In
particular the 50 cent boosted wins (blue thick line) gave rise to a
pronounced increase of activity. By contrast, this increased
response to unexpected high gains was absent in the pramipexole
condition. Percentage bold increase to the boosted +50 condition
under pramipexole was lower (0.58%) than after placebo (0.80%),
t(12)=22.44, p,0.05, potentially reflecting decreased phasic
dopamine release [5].
Additionally, under placebo, unexpected high gains (boost +50)
were associated with higher midbrain activity relative to normal
gains (+5, +25) and +10 boost trials (see Fig. 3b), in line with data
from animal studies (e.g., [6]). Interestingly, this increase in neural
activity was decreased under pramipexole. In addition to the
voxel-based analysis, the BOLD response for a ROI defined
around the peak of activation (x,y,z:24,223,28) was also assessed.
Similarly to the results found in the rostral basal ganglia, the
BOLD increase to the boost +50 trials (dark blue line) was lower
under pramipexole (0.44%) than in the placebo condition (0.58%),
t(12)=22.24, p,0.05.
While our main focus was on the responses in the ventral
striatum and the midbrain, we also found significant activations in
the contrast (standard gain plus boost trials vs. losses) in the
anterior cingulate gyrus (x,y,z coordinates: 26, 43, 7) and the
posterior cingulate gyrus (x,y,z coordinates: 26, 252, 16, see
figure 4) in both, placebo and pramipexole conditions (see [7] for
similar activations).
Discussion
Results in the present study suggest that under pramipexole
subjects make riskier choices following unexpected high wins than
when under placebo. Furthermore, unexpected high wins appear
to loose their highly rewarding quality under pramipexole
treatment, as indicated by the decreased activation of the rostral
basal ganglia This area, especially the ventral striatum, has been
hypothesized to subserve the integration of reward signals in
particular with regard to the planning of future behavior [8].
Additionally, decreased activation was also observed in the
midbrain. The region of blunted activation is at the height of
and appears to include the ventral tegmental area and the
substantia nigra, although the peak coordinates do not coincide
with these regions. A diminished response to unexpected high wins
suggests that integration of reward signals is deficient in the drug
Figure 1. Experimental paradigm. Each trial of the lottery task
comprised the presentation of two numbers, 25 and 5. Participants had
to choose one of two numbers by pressing a corresponding button (left
button for left number). One second after the participant’s selection,
the numbers changed color. Green indicated a win, red a loss. Thus, in
the first (lower) example the subject incurred a loss of 25 Euro cent
(while he could have won 5 Euro cent). The second (upper) example
shows an infrequent ‘‘boost’’ trial in which gains were doubled. See the
Materials and Methods section for further details.
doi:10.1371/journal.pone.0002479.g001
Figure 2. Behavioral results. The relationship between outcome in the previous trial and the probability of making a risky choice (choosing 25) is
shown. Pramipexole significantly increased the probability of making a risky choice following an unexpected ‘‘boost+50’’ trial (left). The error bars
denote 61 standard error of mean.
doi:10.1371/journal.pone.0002479.g002
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could be interpreted as a behavioral attempt to compensate for this
decreased activation. This might be the basis for the high rate of
impulse control disorders in Parkinson’s patients receiving
dopaminergic agonists.
The pharmacologically induced hypoactivation of reward
circuits was analogous to that observed in pathological gamblers
not suffering from neurological disorders [4]. Compulsive
gambling in these patients has been interpreted as an attempt to
compensate for an insufficient dopaminergic activation [4]. In fact,
current theories trying to explain other impulse controls disorders
such as compulsive drug taking postulate that in the transition
from recreational drug use to addiction a decrease in the
functionality of reward systems occurs prior to the instatement
of compulsive drug-seeking behavior [9–11].
Various impulse control disorders characterized by exaggerated
activities with high hedonic value have been described for Parkinson
patients after treatment with dopaminergic agents [3,12]. These
behaviors could constitute maladaptive attempts to recover the
normal operating level of a hypoactive reward system. An
explanation for these undesired side effects may be found in the
interaction of pramipexole with the striatal D2 and D3 receptors. D2
autoreceptor agonism in the striatum has been postulated as the
explanatory mechanism for the observed blunted BOLD signal to
reward predicting stimuli in the NAcc following oral amphetamine in
healthy volunteers [13]. These autoreceptors are located on
presynaptic neurons and serve to regulate neurotransmitter release
by activating negative feedback loops when neurotransmitter
concentrations in the synaptic cleft reach certain levels. Drugs
activating presynaptic autoreceptors are typically able to decrease
neurotransmitter release below physiological levels. Analogously,
excessive chronic dopamine release in the NAcc has been related to a
reduction in the BOLD signal during reward anticipation in
schizophrenics [14]. Regarding D3 receptors, these are located in
the ventral striatum, but also in the midbrain, where they act as
autoreceptors [15]. In this respect, D3 autoreceptor activation has
been found to inhibit the reward-related phasic firing of dopaminer-
gic neurons [15]. D3 receptors have been shown to play a relevant
role in animal models of drug dependence, with D3 antagonists
consistently inhibiting drug-administration and drug-seeking behav-
ior in rodents [16–18]. A D3 receptor mediated inhibition of
midbrain nuclei would be consistent with the reduced midbrain
activation observed under pramipexole in the present study.
In summary, the present findings indicate that the dopamine
D2/D3 receptor agonist pramipexole is capable of blocking
reward-related activations in the rostral basal ganglia and
midbrain and may lead to a behavioral disinhibition characterized
by increases in risky choices in a gambling task. Drug-induced
hyporesponsiveness of reward circuits may underlie the impulse
control disorders observed in Parkinson patients treated with
dopaminergic agonists.
Materials and Methods
All procedures had been approved by the ethical committee of
the University of Magdeburg.
Participants
Fifteen healthy male volunteers participated in the study, which
comprised two experimental sessions. None of the participants had
Figure 3. (a) fMRI results (rostral basal ganglia). Axial slices at z=23
showing voxels of greater activation for win (normal gain+boost) than
loss trials in the ventral striatum after placebo and pramipexole. The
time course of the BOLD response is shown for a ROI defined around
voxel x=215,y=23,z=23 in Talairach coordinates. Results are shown
at p,0.001 uncorrected (n=13). (b) fMRI results (midbrain). Axial slices
at z=28 showing the results of a conjunction analysis conducted to
highlight those voxels where activation following unexpected high
gains (boost+50 trials) was greater than the activation following normal
gain trials and unexpected boost+10 trials after placebo and
pramipexole. The time course of the BOLD response is shown for a
ROI defined around voxel x=24,y=223,z=28 in Talairach coordi-
nates. Results are shown at p,0.0002 uncorrected (n=13). In both
panels (a and b), the color code is as follows: win trials (green; solid: 25
cent wins, dotted: 5 cent wins); loss trials (red; solid: 5 cent loss, dotted:
25 cent loss); boost trials (blue; solid: 50 cent wins, dotted: 10 cent
wins).
doi:10.1371/journal.pone.0002479.g003
Figure 4. fMRI results (cingulate gyrus). Sagittal slices at x=24
showing voxels of greater activation for win (normal gain+boost) than
loss trials in the rostral anterior and posterior cingulate gyrus. Results
are shown at p,0.001 uncorrected (n=13).
doi:10.1371/journal.pone.0002479.g004
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ranged from 20 to 31 years (mean=24.4 years). All subjects gave
their written informed consent and were paid for participation.
Drugs and study design
The study was conducted according to a double-blind
randomized crossover design. All volunteers received the two
study medications, i.e., pramipexole and placebo, each subject
acting thus as his own control. Volunteers participated in two
different experimental sessions, separated at least by one week. On
each experimental session participants received 20 mg domper-
idone in a non-blind fashion in order to antagonize any potential
nausea induced by pramipexole. One hour later they received
either placebo (lactose) or 0.5 pramipexole hydrochloride in a
double blind fashion according to a randomization table. Half of
the subjects received placebo in the first experimental session and
pramipexole in the second. The other half received pramipexole in
the first session and placebo in the second. The fMRI procedures
were started two hours after pramipexole/placebo administration.
Task and stimuli
The experimental paradigm consisted in a lottery task in which
participants had to bet on one of two different numbers, 25 or 5, in
order to increase a starting amount of 500 euro cents. Participants
were instructed to choose one of the two numbers by button press.
One second after the selection, the numbers changed color. Green
indicated a win (i.e., +5o r+25), red a loss (i.e., 25o r225). This
feedback was shown for 2 s. The experimental session comprised
two runs of 94 trials each. In 80 of the 94 trials, the feedback
indicated a standard win or a standard loss. Additionally, in
fourteen of the 94 trials, the so-called ‘‘boost trials’’, wins were
unexpectedly doubled and participants won 10 cents after
choosing 5 (a green ‘‘10’’ was shown as feedback on the screen)
and 50 cents after choosing 25 (a green ‘‘50’’ was shown as
feedback on the screen). Thus, the six possible outcomes were: win
5, win 25, lose 5, lose 25, win 10 (‘‘boost+10’’) and win 50
(‘‘boost+50’’). No boost losses were programmed in the experi-
mental paradigm. Participants were told that they had to adjust
their choices in order to maximize their wins. In actual fact, the
task was programmed to yield wins in 50% of the trials and losses
in the other 50%. Participants were informed on the money they
had won at three different times during each block. A slow event-
related design was used with a constant interstimulus interval of
12 s, during which a fixation cross was presented in the center of
the screen.
Data acquisition and analysis
Acquisition. Data were acquired in a 3-Tesla Siemens
Magnetom Trio Scanner. First, structural images of the brain
were obtained by means of a T1-weighted MPRAGE sequence:
2566256 matrix; field of view (FOV)=256 mm; 192 1-mm sagittal
slices. Subsequently, functional images were obtained in two runs
implementing an echo-planar-imaging sequence. The pulse-
sequence parameters were as follows: time to repeat
(TR)=2000 ms; time to echo (TE)=30 ms; FOV=224 mm; flip
angle (FA)=80u; matrix=64664; slice thickness=4 mm. Thirty-
two transversal slices (3.563.564 mm voxel) were obtained parallel
to the anterior commissure-posterior commissure (AC-PC).
Analysis. Usable data were finally obtained from 13
volunteers. One volunteer withdrew from the study after
complaining of visual distortions which disappeared when he
was removed from the scanner. Another participant invariably
chose ‘‘25’’ in 100% of the trials throughout the two experimental
sessions, thus failing to show any attempt to modulate his behavior
based on prior outcomes.
fMRI. Data analysis included preprocessing (3D motion
correction, slice scan time correction, high-pass temporal
filtering and spatial smoothing with a 4 mm Gaussian filter, full-
width-half-maximum), co-registration and normalization to
Talairach stereotaxic space using Brain Voyager QX. Random-
effects analysis was performed for the functional data (% of BOLD
signal change) including the following predictors: ‘‘win+25’’,
‘‘win+5’’, ‘‘loss-5’’, ‘‘loss-25’’ and ‘‘boost+10’’ and ‘‘boost+50’’
for the placebo and pramipexole conditions. Predictors were
convolved with a two-gamma hemodynamic response function
with the following parameter values: onset=0, time to peak=5 s,
time to undershoot peak=15 s.
Results were considered statistically significant when p values
were lower than 0.001 uncorrected for multiple comparisons.
The time course of the BOLD response was assessed by defining
regions of interest ROIs around the voxel of maximum statistical
difference. The ROIs defined extended 5 voxels in the x,y,z
directions. For direct statistical comparisons of ROI activation in a
given condition between treatments, the maximum percentage of
increase was obtained for each participant and these values
compared by means of pairwise t-tests. Results were considered
statistically significant when p values were lower than 0.05.
Behavior. The probability of making ‘‘risky’’ choices, i.e.,
choosing 25, was measured in relation to the outcome on the
previous trials. These values were analyzed by means of repeated
measures ANOVAs. Factors included treatment (placebo,
pramipexole), type of previous outcome (gain, loss) and
magnitude of outcome (25, 5, ‘‘boost+10’’ and ‘‘boost+50’’).
Results were considered statistically significant when p values were
lower than 0.05.
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